&lt;&lt;Component 1 &gt;&gt; 

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Residual Sleepiness in Obstructive Sleep Apnea: The Role of Inflammation</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Program Introduction</h3>

&lt;&lt;insert slide 2; Timecode (00:00:22). &gt;&gt; 

<h3> Panelists</h3>

&lt;&lt;insert slide 3; Timecode (00:00:40). &gt;&gt; 

<h3> Disclosure</h3>

&lt;&lt;insert intra-activity question 1 (00:00:56)&gt;&gt;

&lt;&lt;insert slide 4; Timecode (00:00:57). &gt;&gt; 

<h3> Segment Introduction </h3>

&lt;&lt;insert slide 5; Chapter Title: Excessive Daytime Sleepiness; Timecode (00:01:25). &gt;&gt; 

<h3> Excessive Daytime Sleepiness in OSA<sup type="ref">[1,2]</sup></h3>

<li>	Trying to understand why these patients remain sleepy or why there is such a strong association with excessive sleepiness is a major problem </li>

&lt;&lt;insert slide 6; Chapter Title: Arousal Threshold and Inflammation; Timecode (00:02:42).  &gt;&gt; 

<h3> Association of the Arousal Threshold with Inflammation and Sleepiness<sup type="ref">[3]</sup></h3>

<li>	Waking up too easily to minor airway narrowing (low respiratory arousal threshold [ArTH]) is a key contributor to obstructive sleep apnea (OSA) pathophysiology</li>

<li>	The extent to which a low ArTH phenotype contributes to daytime sleepiness and inflammation-related clinical sequelae in OSA is unclear</li>

<li>	The aim of this study was to determine whether the ArTH correlated either with inflammatory markers or daytime sleepiness </li>

&lt;&lt;insert slide 7; Timecode (00:03:26). &gt;&gt; 

<h3> Arousal Threshold and Inflammation Study: Results<sup type="ref">[3]</sup></h3>

<li>	When the study was adjusted:

<ul><li>	 The relationship between the ArTH and that of the inflammatory marker C-reactive protein (CRP) disappeared</li>

<li>	There was no relationship between the ArTH and the sleepiness level</li></ul></li>

&lt;&lt;insert slide 8; Arousal Threshold and Depression; Timecode (00:06:05). &gt;&gt; 

<h3>Depression and Arousal Threshold<sup type="ref">[4]</sup></h3>

<li>	In patients with depression, sleep can be disrupted and fragmented</li>

<li>	Sleep disruption could be contributing to the ArTH</li>

&lt;&lt;insert slide 9; Chapter Title: Conclusion; Timecode (00:07:00). &gt;&gt; 

<h3>Concluding Remarks </h3>

&lt;&lt;Component 2 &gt;&gt; 

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Residual Sleepiness in Obstructive Sleep Apnea: Objective and Subjective Markers </strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction</h3>

&lt;&lt;insert slide 2; Chapter Title: EDS in Adequately Treated OSA; Timecode (00:00:22). &gt;&gt; 

<h3></strong> <strong>Excessive Daytime Sleepiness in Patients Adequately Treated With PAP<sup type="ref">[5]</sup></h3>

<li>	This study looked at the correlation between subjective ratings and an objective test

<ul><li>	Subjective -- Epworth Sleepiness Scale (ESS)</li>

<li>	Objective -- Multiple Sleep Latency Test (MSLT)</li></ul></li>

&lt;&lt;insert slide 3;Chapter Title: Methods; Timecode (00:01:11). &gt;&gt; 

<h3> Study Design<sup type="ref">[5]</sup></h3>

<li>	Actigraphy approximates how stable a patient's sleep-wake cycle is and their sleep duration</li>

&lt;&lt;insert slide 4; Timecode (00:02:27). &gt;&gt; 

<h3> Study Design (cont)<sup> [5]</sup></h3>

<li>	Mean sleep-onset latency over the 5 naps was assessed</li>

<li>	 MSLT measures the time to fall asleep</li>

&lt;&lt;insert slide 5; Chapter Title: Methods; Timecode (00:03:30). &gt;&gt; 

<h3> Demographic Characteristics<sup type="ref">[5]</sup>  </h3>

<li>	Study population included mostly men with a mean ESS score of 16.3</li>

<li>	Even among patients with OSA, that is a lot of subjective sleepiness</li>

&lt;&lt;insert slide 6; Chapter Title: Results; Timecode (00:04:20). &gt;&gt; 

<h3>Results<sup type="ref">[5]</sup></h3>

<li>	Despite adequate treatment and low Apnea&#160;Hypopnea Index (AHI), 31% were pathologically hypersomnolent</li>

&lt;&lt;insert slide 7; Chapter Title: Conclusion; Timecode (00:04:47). &gt;&gt; 

<h3>Conclusion</h3>

<li>	Findings:

<ul><li>	Not a strong correlation between subjective ratings of sleepiness and that of the objective measure (the MSLT)</li>

<li>	Recommendations:

<ul><li>	Important to measure both the subjective and objective measures</li>

<li>	Very important to obtain actigraphic evaluation to see how well patients are sleeping</li></ul></li></ul></li>

&lt;&lt;Component 3  &gt;&gt;

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>The Treatment of Narcolepsy in Adults: Emerging Therapies</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction</h3>

&lt;&lt;insert slide 2; Chapter Title: Solriamfetol:; Timecode (00:00:30). &gt;&gt; 

<h3> Solriamfetol<sup type="ref">[6,7]</sup></h3>

<li>	Solriamfetol affects both norepinephrine and dopamine</li>

<li>	Most medications used for narcolepsy affect only dopamine</li>

<li>	Both neurotransmitters are very important in the control of sleep and wakefulness

<ul><li>	Increasing dopamine has an effect on improving alertness </li>

<li>	Norepinephrine may have an effect on inhibiting sleep drive </li></ul></li>

&lt;&lt;insert slide 3; Timecode (00:01:44). &gt;&gt; 

<h3>Solriamfetol: Treatment of ES in Narcoleptic Patients With and Without Cataplexy<sup type="ref">[7]</sup></h3>

<li>	12-week, placebo-controlled study </li>

<li>	Assessed main measures for sleepiness

<ul><li>	Maintenance of Wakefulness Test (MWT) -- an objective measure </li>

<li>	ESS -- a subjective measure </li></ul></li>

&lt;&lt;insert slide 4; Chapter Title:Study Results; Timecode (00:02:07). &gt;&gt; 

<h3>Solriamfetol: MWT Results<sup type="ref">[7,8]</sup></h3>

<li>	MWT measures the ability to stay awake under soporific conditions using a daytime polysomnographic procedure</li>

<li>	Throughout the 12-week study, improvements with both the 300- and 150-mg doses were seen at all timepoints</li>

&lt;&lt;insert slide 5; Chapter Title:Study Conclusions; Timecode (00:03:54). &gt;&gt; 

<h3> Conclusions<sup type="ref">[7]</sup></h3>

&lt;&lt;insert slide 6; Timecode (00:04:17). &gt;&gt; 

<h3> Conclusions: Adverse Events<sup type="ref">[7]</sup></h3>

<li>	No significant major adverse events (AEs) seen throughout the study</li>

&lt;&lt;insert slide 7; Chapter Title: Use in Practice; Timecode (00:04:47). &gt;&gt; 

<h3> Possible Use in Clinical Practice</h3>

&lt;&lt;insert slide 8; Chapter Title; Pitolisant Timecode (00:05:25). &gt;&gt; 

<h3> Pitolisant<sup type="ref">[9]</sup></h3>

<li>	Pitolisant increases histamine levels in the brain

<ul><li>	Histamine is an important neurotransmitter that plays a role in alertness</li></ul></li>

<li>	It is a once-a-day medication taken in the morning</li>

<li>	It has become available in the United States under an early access program; it is not yet approved by the US Food and Drug Administration for any use</li>

&lt;&lt;insert slide 9; Chapter Title; Pitolisant Studies Timecode (00:06:45). &gt;&gt; 

<h3> Anticataplectic Efficacy of Pitolisant<sup type="ref">[9]</sup></h3>

&lt;&lt;insert slide 10; Timecode (00:07:06). &gt;&gt; 

<h3> Double-Blind, 7-Week Study of Pitolisant vs Placebo: Results<sup type="ref">[9]</sup></h3>

&lt;&lt;insert slide 11; Timecode (00:07:15). &gt;&gt; 

<h3> Open-Label, 12-Month Study of Pitolisant: Results<sup type="ref">[9]</sup></h3>

<li>	Improvement in weekly rate of cataplexy (WRC) was observed at month 1 and was maintained through month 12</li>

&lt;&lt;insert slide 12; Timecode (00:07:38) . &gt;&gt; 

<h3> Long-Term Evaluation of Pitolisant Safety and Efficacy in Narcolepsy<sup type="ref">[9]</sup></h3>

<li>	This medication has a good safety profile</li>

<li>	No major AEs were seen with pitolisant in this study</li>

&lt;&lt;Component  4 &gt;&gt;

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction</h3>

&lt;&lt;insert slide 2; Chapter Title: Upper Airway Stimulation; Timecode (00:00:43). &gt;&gt; 

<h3> Upper Airway Stimulation Therapy<sup type="ref">[10]</sup></h3>

<li>	This therapy is directed at the anatomic factors causing OSA using technology and a device</li>

<li>	It uses nerve stimulation to open the airway during sleep</li>

&lt;&lt;insert slide 3; Timecode (00:01:10). &gt;&gt; 

<h3> Upper Airway Stimulation </h3>

<li>	Implanted device is comprised of a stimulator implanted on the hypoglossal nerve and a sensor implanted in the chest</li>

<li>	The sensor detects breathing and sends an electrical current to the nerve when the airway needs to open during sleep</li>

<li>	This is the first therapy to directly act on the nerve </li>

&lt;&lt;insert slide 4; Chapter Title: Indications; Timecode (00:02:15). &gt;&gt; 

<h3> Indications for Use<sup type="ref">[11]</sup></h3>

&lt;&lt;insert slide 5; Chapter Title: ADHERE Registry Subanaylsis; Timecode (00:03:15). &gt;&gt; 

<h3> ADHERE Registry Analysis<sup type="ref">[12,13]</sup></h3>

<li>	The ADHERE Registry is not FDA mandated </li>

<li>	Measures real-world outcomes of upper airway stimulation (UAS)</li>

&lt;&lt;insert slide 6; Timecode (00:04:00) . &gt;&gt; 

<h3> ADHERE Registry Analysis: Results<sup type="ref">[12]</sup></h3>

&lt;&lt;insert slide 7; Timecode  (00:04:53) . &gt;&gt; 

<h3> Upper Airway Stimulation for OSA: 5-Year Outcomes<sup type="ref">[14]</sup></h3>

<li>	The 5-year follow-up of the original study showed that patients who initially respond well to UAS continued to respond well for 5 years</li>

&lt;&lt;insert slide 8; Chapter Title: BMI and UAS; Timecode (00:05:13) . &gt;&gt; 

<h3> Association of BMI and UAS Success<sup type="ref">[12]</sup></h3>

&lt;&lt;Component 5 &gt;&gt;

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>The Impact of Upper Airway Stimulation on Sleepiness and Blood Pressure in Obstructive Sleep Apnea</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction</h3>

&lt;&lt;insert slide 2; Chapter Title: Comparative Study of ESS and BP; Timecode (00:00:24). &gt;&gt; 

<h3> Comparing UAS and PAP Effects on ESS and BP<sup type="ref">[15]</sup></h3>

 &lt;&lt;insert slide 3; Chapter Title: Comparative Study Results; Timecode (00:00:50). &gt;&gt; 

<h3> Results<sup type="ref">[15]</sup></h3>

<li>	Results showed a slightly better effect on ESS scores with upper airway stimulation (UAS) than continuous positive airway pressure (CPAP) </li>

<li>	There was no change in blood pressure</li>

&lt;&lt;insert slide 4; Chapter Title: Comparative Study Conclusions; Timecode (00:01:10)  . &gt;&gt; 

<h3> Conclusions<sup type="ref">[15]</sup></h3>

&lt;&lt;insert slide 5; Chapter Title: Effects of Hypoglossal Nerve Stimulation; Timecode (00:02:00). &gt;&gt; 

<h3> Effects of HNS on Sleep Architecture and MWT in OSA<sup type="ref">[16]</sup></h3>

<li>	Hypoglossal nerve stimulation (HNS) is a novel therapy for patients with OSA that has been shown to reduce AHI</li>

<li>	This study evaluated the impact of HNS on sleep architecture and objective level of alertness</li>

&lt;&lt;insert slide 6; Timecode (00:03:00) . &gt;&gt; 

<h3> Effects of HNS on Sleep Architecture and MWT in OSA: Conclusions<sup type="ref">[16]</sup></h3>

<li>	UAS is tunable during and after implantation</li>

&lt;&lt;Component 6&gt;&gt;

<strong>&lt;&lt;Level 1&gt;&gt; The Diagnosis of Pediatric Narcolepsy: The Role of Biomarkers</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction </h3>

&lt;&lt;insert slide 2; Chapter Title: Diagnostic Delays; Timecode (00:00:50). &gt;&gt; 

<h3>Diagnostic Challenges in Childhood Narcolepsy<sup type="ref">[17]</sup></h3>

<li>	Diagnostic delays are very common in children and adolescents with narcolepsy </li>

<li>	It can take many years for the disease to be recognized and diagnosed</li>

<li>	This study looked for additional biomarkers in the polysomnogram that could help improve diagnostic accuracy and determine the epidemiology of pediatric narcolepsy</li>

&lt;&lt;insert slide 3; Chapter Title: Biomarkers  ; Timecode (00:02:35). &gt;&gt; 

<h3>REM Sleep<sup type="ref">[18,19]</sup></h3>

<li>	In normal rapid eye movement (REM) sleep, there is almost no muscle tone, ie, REM atonia </li>

<li>	Children and adults with narcolepsy have increased muscle tone during REM sleep, ie, REM without atonia (nRWA)</li>

<li>	This study looked at whether nRWA could serve as a biomarker of narcolepsy</li>

&lt;&lt;insert slide 4; Timecode (00:03:16). &gt;&gt; 

<h3>Diagnostic Biomarker: nRWA<sup type="ref">[18]</sup></h3>

<li>	This study used the American Academy of Sleep Medicine (AASM) criteria to score nRWA </li>

&lt;&lt;insert slide 5; Timecode (00:04:25). &gt;&gt; 

<h3>Diagnostic Biomarker: nRWA Results<sup type="ref">[18]</sup></h3>

<li>	Data from patients with narcolepsy type 1 and type 2 were combined to determine whether nRWA was a significant biomarker that separated them from other groups of patients</li>

&lt;&lt;insert slide 6; Chapter Title: Pediatric Disruptive Nighttime Sleep; Timecode (00:05:38). &gt;&gt; 

<h3>DNS in Children and Adolescents With Narcolepsy<sup type="ref">[20]</sup></h3>

<li>	Because it is not known how to objectively define disrupted nighttime sleep (DNS) in pediatric narcolepsy, this study sought to examine this parameter</li>

<li>	Studies were rescored using AASM criteria to eliminate confounding of different scoring criteria and scorers</li>

&lt;&lt;insert slide 7; Timecode (00:06:39). &gt;&gt; 

<h3> DNS in Children and Adolescents With Narcolepsy Findings<sup type="ref">[20]</sup></h3>

&lt;&lt;Component 7  &gt;&gt;

<strong>&lt;&lt;Level 1&gt;&gt;</strong> <strong>Advances in Treating Pediatric Narcolepsy</strong>

&lt;&lt;insert slide 1; Chapter Title: Introduction; Timecode (00:00:00). &gt;&gt; 

<h3> Introduction</h3>

&lt;&lt;insert slide 2; Chapter Title: Sodium Oxybate Study; Timecode (00:00:25). &gt;&gt; 

<h3>Sodium Oxybate in Children and Adolescents with Narcolepsy: Study Design<sup type="ref">[21]</sup></h3>

<strong><li>	</strong>Several presentations and posters focused on providing additional data from the pediatric sodium oxybate trial that was conducted last year</li>

&lt;&lt;insert slide 3; Chapter Title: Study Results; Timecode (00:00:57). &gt;&gt; 

<h3>Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period<sup type="ref">[21]</sup></h3>

<strong><li>	 </strong>Ruoff and colleagues examined the results of the Clinical Global Impression scales </li>

&lt;&lt;insert slide 4; Timecode (00:01:40). &gt;&gt; 

<h3> Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period (cont)<sup type="ref">[21]</sup></h3>

&lt;&lt;insert slide 5;Chapter Title: Adverse Events; Timecode (00:02:40). &gt;&gt; 

<strong>&lt;&lt;Level 2&gt;</strong> <strong>Sodium Oxybate: Assessment at the End of the Double-Blind Withdrawal Period (cont)<sup type="ref">[21]</sup></strong>

<strong><li>	</strong>More than 10% of patients reported the following AEs: nocturnal enuresis, nausea, vomiting, headache, and weight loss</li>

&lt;&lt;insert slide 6; Chapter Title: Effects on Development; Timecode (00:02:56) . &gt;&gt; 

<strong>&lt;&lt;Level 2&gt;Effects of Sodium Oxybate on Weight, Height, and Pubertal Development<sup type="ref">[22,23,24]</sup></strong>

<strong><li>	</strong>Obesity and being overweight is a clinical problem in pediatric narcolepsy </li>

<strong><li>	</strong>In this study, the investigators looked at how weight, height, and puberty changed with sodium oxybate use over 1 year </li>

&lt;&lt;insert slide 7;Timecode(00:03:38) . &gt;&gt; 

<strong>&lt;&lt;Level 2&gt;Effects of Sodium Oxybate on Weight, Height, and Pubertal Development: Study Findings<sup type="ref">[22]</sup></strong>

<strong><li>	</strong>When the study began, 64.2% of study participants were categorized as being obese or overweight</li>

<strong><li>	</strong>Gradual weight loss occurred in participants over 1 year</li>

<strong><li>	</strong>By the end of this study, more subjects were in the normal-weight category, and fewer were obese or overweight (9% fewer)</li>

&lt;&lt;insert slide 8; Chapter Title: Long-term Effects; Timecode (00:04:20). &gt;&gt; 

<strong>&lt;&lt;Level 2&gt;</strong> <strong>Long-Term Effects of Sodium Oxybate in Pediatric Patients<sup type="ref">[25]</sup></strong>

<strong><li>	</strong>Cataplexy control and daytime sleepiness remained fairly stable during the 1-year period </li>

<strong><li>	</strong>Depression, anxiety scores, and suicidality measures remained within the average range during the study </li>

&lt;&lt;insert slide 9; Chapter Title: Disease Burden Analysis; Timecode (00:05:24). &gt;&gt; 

<strong>&lt;&lt;Level 2&gt;</strong> <strong>Disease Burden in Pediatric Narcolepsy<sup type="ref">[26]</sup></strong>

<strong><li>	</strong>This claims-based analysis of healthcare utilization assessed demand and costs in a group of children and adolescents with narcolepsy </li>

&lt;&lt;insert slide 10; Chapter Title: Thank you; Timecode (00:06:31). &gt;&gt;  

<strong>&lt;&lt;Level 2&gt;</strong> <strong>Thank You</strong>

<strong><em>Mandatory Insertion after Main CONTENT with abridged Transcripts:</em></strong>

<em>This content has been condensed for improved clarity.</em>